$MYOS huge news out! Astronaut Buzz Aldrin Relies on Re

New Post Public Reply Private Reply Replies (0) Message Board
BCNstocks
$MYOS huge news out! Astronaut Buzz Aldrin Relies on Re Muscle Health(TM) Products to Help Rebuild, Rejuvenate and Maintain Lean Muscle!

Important to note: Fortetropin(R), the Ingredient in Re Muscle Health(TM), Is Clinically Proven to Maintain Lean Muscle

TN-87213_reImage_original.jpg

http://finance.yahoo.com/news/astronaut-buzz-...00507.html

CEDAR KNOLLS, NJ--(Marketwired - May 19, 2015) - MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that astronaut Dr. Buzz Aldrin, a paid member of the Company's board of directors and spokesman, uses Re Muscle Health™ products daily along with regular exercise to help maintain lean muscle at the age of 85.

Rē Muscle Health™ is a new product line that helps rebuild, rejuvenate and maintain lean muscle and is designed for individuals who want an all-natural product with clinically proven results. Fortetropin®, the active ingredient in Rē Muscle Health™, is clinically proven to build healthy lean muscle. It accomplishes this through a fertilized egg based protein and lipid complex that increases protein synthesis and inhibits muscle degradation pathways.

Rē Muscle Health™ products contain 20 grams of protein to help protect, preserve and promote healthy lean muscle. Rē Muscle Health™ Bars, powders and meal replacement shakes can be used daily:

- To increase both muscle thickness and lean body mass
- For workout recovery -- protein helps promote muscle recovery and growth
- As a snack or meal replacement

The Rē Muscle Health™ Series comes in six flavors, and can be ordered online at www.remusclehealth.com.

Dr. Aldrin commented, "I recognize the importance of maintaining muscle health and maximizing muscle performance. Given the extraordinary rigors of space travel on the human body, as well as the physical challenges of living in a zero gravity environment, unraveling the biology around muscle loss occurring during weightlessness and as a consequence of illness and immobility is one of the great opportunities I see for MYOS to develop therapeutic solutions in the future."

"MYOS is doing important, groundbreaking work in muscle health, and I rely on Re Muscle Health™ products to help me maintain my lean muscle, they taste great and I've seen tremendous results." Dr. Aldrin, a former intercollegiate athlete and pole vaulter, also noted, "I am pleased that Re Muscle Health™ is tailored to the aging population as well as athletes and the fitness community."

Chairman of MYOS Robert J. Hariri, M.D., Ph.D., commented "I am delighted to have Buzz as a member of the MYOS Board of Directors and as an advocate for our Re Muscle Health™ products. Buzz is a true American hero, a distinguished leader and businessman, a great mentor to me personally and an example of how physically active we can all be throughout our lives. I can tell you that Dr. Aldrin's demanding physical lifestyle in his 80's is an example of what we all should aspire to maintain."

About Buzz Aldrin
Buzz was educated at the U.S. Military Academy at West Point, graduating third in his class with a B.S. in mechanical engineering. He then joined the Air Force, serving as a combat pilot in Korea where he was decorated with the Distinguished Flying Cross and later retired with the rank of Colonel. He went on to earn his Doctorate of Science in Astronautics at the Massachusetts Institute of Technology and wrote his thesis on manned orbital rendezvous. Selected as an astronaut by NASA in 1963, Aldrin was the first astronaut with a doctorate.

In 1966 on the Gemini 12 orbital mission, Buzz performed the world's first successful spacewalk, overcoming prior difficulties experienced by Americans and Russians during extra-vehicular activity (EVA), and setting a new EVA record of 5 1/2 hours. On July 20, 1969, Buzz and Neil Armstrong made their historic Apollo 11 moonwalk, becoming the first two humans to set foot on another world. They spent 21 hours on the lunar surface and returned with 46 pounds of moon rocks. An estimated 600 million people -- at that time, the world's largest television audience in history -- witnessed this unprecedented heroic endeavor. Upon returning from the moon, Buzz was decorated with the Presidential Medal of Freedom, the highest American peacetime award.

Since retiring from NASA and the Air Force, Dr. Aldrin has remained at the forefront of efforts to ensure America's continued leadership in human space exploration. He devised a master plan for missions to Mars known as the "Aldrin Mars Cycler" -- a spacecraft system with perpetual cycling orbits between Earth and Mars. Dr. Aldrin has received three U.S. patents for his schematics of a modular space station, Starbooster reusable rockets, and multi-crew modules for space flight. He founded Starcraft Boosters, Inc., a rocket design company, and the ShareSpace Foundation, a nonprofit devoted to advancing space education, exploration and affordable space flight experiences for all. Dr. Aldrin is an author of seven books including his New York Times bestselling autobiography titled, "Magnificent Desolation" which was released in 2009. For more information, please visit www.buzzaldrin.com.

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com

About Rē Muscle Health™

The Rē Muscle Health™ series is the Company's first branded line of muscle health products. This unique line of all-natural, non-GMO products contain Fortetropin®, an egg-based, all natural myostatin inhibitor clinically proven to build healthy muscle. The Rē Muscle Health™ series can be ordered by visiting www.remusclehealth.com. MYOS believes that Fortetropin®, as well as future products it envisions, will redefine existing standards for muscle health. The Rē Muscle Health™ product line is owned and sold directly by the Company. www.remusclehealth.com

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, the successful launch and customer demand for our Rē Muscle Health™ and other products, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin® and Rē Muscle Health™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Contact:
Lindsey Penrose
Vice President Business Development
(973) 509-0444
Email Contact
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

Updated Category News Views 191

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

Continue Reading
West Virginia's Water Upgrade: AWK's Strategic Moves

Updated Category News Views 6

Building a Water Infrastructure with Purpose Well, they ain't just whistling Dixie down in Ranson, West Virginia. American Water's been busy putting their money where their mouth is with this new 816,000-gallon tank. When you look at the bigger picture, it ain't just about a shiny new water storage toy. Nah, this is about setting the stage for long-term resilience in the...

Continue Reading
NAMSA, AMS Partner to Fast-Track Tissue-Healing Tech

Updated Category News Views 41

Streamlining the Path to Market I tell you, the medical device sector is no walk in the park these days. Between the regulators breathing down your neck and the endless red tape, getting a new product from the lab to the hospital floor can feel like running a marathon in quicksand. That's why this deal between NAMSA and Advanced Medical Solutions (AMS) has me taking a...

Continue Reading
Paratus Energy Lands Petrobras Tender, Ties Finalizing

Updated Category News Views 64

Seagems Joint Venture Snags Petrobras Contract Let’s dive headfirst into this business update, because this one's got teeth, folks. Petrobras, the big dog in Brazil’s oil arena, has given the green light to Seagems’ bid, a joint venture half-owned by Paratus Energy Services Ltd. The target? A hefty pipe-laying support vessel (PLSV) contract starting in 2028. But...

Continue Reading
KT&G Launches Heated Tobacco in Kazakhstan's Market

Updated Category News Views 99

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Continue Reading
Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Updated Category News Views 102

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Continue Reading
Middleby Under Scrutiny: Shareholder Investigation Alert

Updated Category News Views 10

Middleby Shareholders in the Crosshairs There's hot soup boiling over at The Middleby Corporation (NASDAQ: MIDD). A shareholder investigation is underway, spearheaded by Purcell & Lefkowitz LLP, a firm that jumps into the fray when there’s a whiff of fiduciary breaches in corporate dealings. As I see it, this kind of legal sniffing around often stirs the pot—raising...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 345

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
UAE Pioneers eATA Carnet System Beyond Europe

Updated Category News Views 139

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 353

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading

Top 5 Most Recently Viewed Articles

Danish Ship Finance A/S Unveils Key Insights for 2025

Updated Category News Views 240

Insights from the Interim Report of Danish Ship Finance A/S Danish Ship Finance A/S has recently released its interim report outlining financial performance and various noteworthy developments for the first half of 2025. This report offers stakeholders a comprehensive view of the company's financial health and future prospects. Financial Performance Overview In the first...

Continue Reading
Verses AI Secures $20 Million to Advance Innovative Technologies

Updated Category News Views 207

Verses AI Inc. Makes Significant Strides with Funding Closure Verses AI Inc. is proud to share that it has successfully closed a substantial funding round, amounting to approximately C$20,000,000. This achievement marks a pivotal moment for the Company, indicating robust interest and confidence from investors in its innovative offerings. Details of the Offering The recent...

Continue Reading
Understanding Unite Group Plc's Recent Securities Disclosure

Updated Category News Views 186

Key Information Regarding Unite Group Plc In recent updates surrounding Unite Group Plc, significant information has emerged concerning the disclosure made by Rathbones Group Plc. This revolves around the interests in relevant securities that exceed 1% as mandated by the UK Takeover Code. Full Disclosure Body The disclosure initiated by Rathbones Group Plc states their...

Continue Reading
StakingBonus Launches Innovative Multi-Chain Staking Options

Updated Category News Views 299

StakingBonus Launches Innovative Multi-Chain Staking Options StakingBonus, a prominent crypto staking solutions provider, has recently made headlines with its exciting launch of multi-chain staking solutions. This advancement marks an important milestone in the firm's growth strategy, allowing cryptocurrency investors to expand their opportunities for yield and security....

Continue Reading
Ensign Group to Share Insights at Upcoming Healthcare Event

Updated Category News Views 140

Exciting Presentation from Ensign Group The Ensign Group, Inc. (Nasdaq: ENSG), a prominent provider in the skilled nursing and senior living services sector, has announced its participation in a key upcoming event. The company will be presenting at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference, an event dedicated to showcasing leaders in the...

Continue Reading